Filovirus scFv Antibodies Broad-Spectrum Detection
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for detecting and treating filovirus infections, such as those caused by ebolaviruses and marburgviruses, are limited by the lack of effective, broad-spectrum diagnostic tools and therapeutic agents.
Innovation Solution
Development of a panel of mouse single-chain Fv-antibodies (scFvs) that specifically bind to filovirus glycoproteins using cell-free ribosome display technology, enabling broad-spectrum detection and potential therapeutic applications.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current diagnostic methods are used for filovirus infections, then existing tools can be applied, but they lack broad-spectrum effectiveness and specificity
Solution Approach 1:
The patent develops a panel of scFv antibodies that can detect multiple filovirus species (Ebolavirus and Marburgvirus) using a single diagnostic approach. The antibodies are designed to recognize conserved epitopes across different filovirus glycoproteins, enabling one diagnostic system to serve multiple detection purposes rather than requiring separate assays for each virus type.
2Reliability
If current therapeutic agents are used for filovirus infections, then existing treatments can be administered, but they lack effectiveness as broad-spectrum therapeutics
Solution Approach 1:
The patent creates therapeutic scFv antibodies that can neutralize multiple filovirus species through a single administration. The antibodies target conserved regions of filovirus glycoproteins that are essential for viral entry and replication, allowing one therapeutic agent to provide protection against diverse filovirus threats rather than requiring virus-specific treatments.
3Productivity
If cell-free ribosome display technology is used to generate scFvs, then rapid antibody production is achieved, but the complexity of the technology increases
Solution Approach 1:
The patent replaces traditional cell-based antibody production methods with cell-free ribosome display technology. This substitution eliminates the need for living cell cultures, complex biological systems, and lengthy purification protocols, achieving rapid antibody generation through in vitro transcription-translation systems followed by direct panning on target antigens.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The scFvs demonstrate strong cross-reactivity with all known pathogenic filoviruses, offering a promising diagnostic tool and potential therapeutic agent for filovirus infections.
Implementation Method 1
a panel of mouse single-chain Fv-antibodies (scFvs) that specifically bind to filovirus glycoproteins
Data Source
AI summary
An antibody that binds to a filovirus glycoprotein generally includes include a complementarity determining region (CDR) of any one of SEQ ID NO:27-36 or a combination of such CDRs. The antibody may be used in to detect filovirus in a biological sample obtained from a subject. The antibody also may be formulated into a pharmaceutical composition for administering to a subject having, or at risk of having, a filovirus infection.